Literature DB >> 19874153

High-dose naltrexone therapy for cocaine-alcohol dependence.

Joy M Schmitz1, Jan A Lindsay, Charles E Green, David V Herin, Angela L Stotts, F Gerard Moeller.   

Abstract

This randomized, double-blind, placebo-controlled study compared the effects of high-dose (100 mg/d) naltrexone versus placebo in a sample of 87 randomized subjects with both cocaine and alcohol dependence. Medication conditions were crossed with two behavioral therapy platforms that examined whether adding contingency management (CM) that targeted cocaine abstinence would enhance naltrexone effects compared to cognitive behavioral therapy (CBT) without CM. Primary outcome measures for cocaine (urine screens) and alcohol use (timeline followback) were collected thrice-weekly during 12 weeks of treatment. Retention in treatment and medication compliance rates were low. Rates of cocaine use and drinks per day did not differ between treatment groups; however naltrexone did reduce frequency of heavy drinking days, as did CBT without CM. Notably, adding CM to CBT did not enhance treatment outcomes. These weak findings suggest that pharmacological and behavioral interventions that have shown efficacy in the treatment of a single drug dependence disorder may not provide the coverage needed when targeting dual drug dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19874153      PMCID: PMC2907651          DOI: 10.3109/10550490903077929

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  29 in total

1.  The effects of naltrexone on alcohol and cocaine use in dually addicted patients.

Authors:  D W Oslin; H M Pettinati; J R Volpicelli; A L Wolf; K M Kampman; C P O'Brien
Journal:  J Subst Abuse Treat       Date:  1999-03

2.  Treatment outcome of cocaine-alcohol dependent patients.

Authors:  J M Schmitz; P S Bordnick; M L Kearney; S M Fuller; J K Breckenridge
Journal:  Drug Alcohol Depend       Date:  1997-07-25       Impact factor: 4.492

Review 3.  A meta-analysis of voucher-based reinforcement therapy for substance use disorders.

Authors:  Jennifer Plebani Lussier; Sarah H Heil; Joan A Mongeon; Gary J Badger; Stephen T Higgins
Journal:  Addiction       Date:  2006-02       Impact factor: 6.526

4.  Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.

Authors:  James C Garbutt; Henry R Kranzler; Stephanie S O'Malley; David R Gastfriend; Helen M Pettinati; Bernard L Silverman; John W Loewy; Elliot W Ehrich
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

Review 5.  Treatment effectiveness score as an outcome measure in clinical trials.

Authors:  W Ling; S Shoptaw; D Wesson; R A Rawson; M Compton; C J Klett
Journal:  NIDA Res Monogr       Date:  1997

6.  Relapse prevention treatment for cocaine dependence: group vs. individual format.

Authors:  J M Schmitz; L M Oswald; S D Jacks; T Rustin; H M Rhoades; J Grabowski
Journal:  Addict Behav       Date:  1997 May-Jun       Impact factor: 3.913

7.  Medication take-home doses and contingency management.

Authors:  J M Schmitz; H M Rhoades; R Elk; D Creson; I Hussein; J Grabowski
Journal:  Exp Clin Psychopharmacol       Date:  1998-05       Impact factor: 3.157

8.  Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer.

Authors:  F K Del Boca; H R Kranzler; J Brown; P F Korner
Journal:  Alcohol Clin Exp Res       Date:  1996-11       Impact factor: 3.455

9.  Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.

Authors:  James Poling; Alison Oliveto; Nancy Petry; Mehmet Sofuoglu; Kishorchandra Gonsai; Gerardo Gonzalez; Bridget Martell; Thomas R Kosten
Journal:  Arch Gen Psychiatry       Date:  2006-02

10.  Naltrexone treatment of comorbid alcohol and cocaine use disorders.

Authors:  D Hersh; J R Van Kirk; H R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  1998-09       Impact factor: 4.530

View more
  16 in total

Review 1.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

2.  Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.

Authors:  Marsida Kallupi; Qianwei Shen; Giordano de Guglielmo; Dennis Yasuda; V Blair Journigan; Nurulain T Zaveri; Roberto Ciccocioppo
Journal:  Addict Biol       Date:  2017-06-21       Impact factor: 4.280

3.  Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.

Authors:  Sarah Sushchyk; Zheng-Xiong Xi; Jia Bei Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-02-22       Impact factor: 4.030

4.  Investigating Methamphetamine Craving Using the Extinction-Reinstatement Model in the Rat.

Authors:  Peter R Kufahl; M Foster Olive
Journal:  J Addict Res Ther       Date:  2011-11-15

5.  Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys.

Authors:  Megan J Moerke; Matthew L Banks; Kejun Cheng; Kenner C Rice; S Stevens Negus
Journal:  Drug Alcohol Depend       Date:  2017-10-13       Impact factor: 4.492

Review 6.  Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.

Authors:  A C Del Re; Natalya Maisel; Janet C Blodgett; Paula Wilbourne; John W Finney
Journal:  J Clin Psychopharmacol       Date:  2013-10       Impact factor: 3.153

Review 7.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

Review 8.  Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.

Authors:  Shih-Ku Lin
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

9.  A two-phased screening paradigm for evaluating candidate medications for cocaine cessation or relapse prevention: modafinil, levodopa-carbidopa, naltrexone.

Authors:  Joy M Schmitz; Charles E Green; Angela L Stotts; Jan A Lindsay; Nuvan S Rathnayaka; John Grabowski; F Gerard Moeller
Journal:  Drug Alcohol Depend       Date:  2014-01-03       Impact factor: 4.492

Review 10.  Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.

Authors:  Julia M A Sinclair; Sophia E Chambers; Celia J Shiles; David S Baldwin
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.